LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Lista de Ações・Coherus Oncology Inc

Coherus Oncology Inc

Fechado

SetorSaúde

1.56 -4.29

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.55

Máximo

1.56

Indicadores-chave
By Trading Economics
Rendimento	-280M -38M
Vendas	-438K 12M
P/E Médio do Setor	3.509 51.415
Margem de lucro	-311.348
Funcionários	147
EBITDA	7.1M -36M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+425.48% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	33M 292M
Abertura anterior	5.85
Fecho anterior	1.56

Sentimento de Notícias

By Acuity

88%

12%

327 / 345 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

0.9209 / 1.05 Suporte e Resistência

Coherus Oncology Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

15 de mai. de 2026, 22:47 UTC

Ações em Alta

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 de mai. de 2026, 22:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 de mai. de 2026, 22:00 UTC

Grandes Movimentos do Mercado

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 de mai. de 2026, 18:09 UTC

Grandes Movimentos do Mercado

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15 de mai. de 2026, 16:02 UTC

Ganhos

Grandes Movimentos do Mercado

Forward Industries Shares Fall on New Debt as Solana Value Drops

15 de mai. de 2026, 14:55 UTC

Grandes Movimentos do Mercado

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

16 de mai. de 2026, 16:27 UTC

Aquisições, Fusões, Aquisições de Empresas

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 de mai. de 2026, 08:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

15 de mai. de 2026, 22:17 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 de mai. de 2026, 21:59 UTC

Aquisições, Fusões, Aquisições de Empresas

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 de mai. de 2026, 21:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 de mai. de 2026, 21:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 de mai. de 2026, 21:16 UTC

Conversa de Mercado

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

15 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

15 de mai. de 2026, 20:19 UTC

Ações em Alta

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 de mai. de 2026, 19:41 UTC

Aquisições, Fusões, Aquisições de Empresas

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 de mai. de 2026, 19:35 UTC

Conversa de Mercado

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 de mai. de 2026, 19:33 UTC

Conversa de Mercado

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 de mai. de 2026, 18:35 UTC

Ganhos

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15 de mai. de 2026, 17:28 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15 de mai. de 2026, 16:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15 de mai. de 2026, 16:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

15 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

15 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

15 de mai. de 2026, 15:55 UTC

Conversa de Mercado

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15 de mai. de 2026, 15:20 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 de mai. de 2026, 15:20 UTC

Conversa de Mercado

Silver Plunges on Inflation Worries -- Market Talk

15 de mai. de 2026, 15:20 UTC

Ganhos

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

Comparação entre Pares

Variação de preço

Coherus Oncology Inc Previsão

Preço-alvo

By TipRanks

425.48% parte superior

Previsão para 12 meses

Média 8.25 USD 425.48%

Máximo 12 USD

Mínimo 4 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Coherus Oncology Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

Comprar

Manter

Vender

Com base em 5 analistas que deram avaliações de ações para Coherus Oncology Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

0.9209 / 1.05Suporte e Resistência

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentimento

By Acuity

327 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.